Skip to main content

ACR 2022 Tweet by Mike Putman

View on
Exciting time to be doing research in GCA! Over half a dozen ongoing RCTs

Challenging to recruit enough patients given (1) competing trials (2) reticence to join a trial when tocilizumab (standard of care) is available

#ACR22 #Vasculitis22 @RheumNow
Image from Mike Putman’s tweet
×